Aroa Biosurgery Ltd (AU:ARX) has released an update.
Aroa Biosurgery Limited has reported a strong performance for the quarter ending September 2024, with a 35% increase in cash receipts to NZ$19.9 million and a significant reduction in cash burn. The company remains debt-free with a robust cash balance of NZ$21.6 million and maintains its revenue guidance for FY25, while expanding its market presence in the US, Argentina, and Egypt.
For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
